explore -WSS

explore

author：leisure time 2025-10-01 00:59:28 - browse：92

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Hubble vs. James Webb telescope images: See the difference

leisure time

WSS

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Drug cartel violence flares in western Mexico after vigilante leader's killing

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

US jobless claims fall again as labor market continues to flash strength

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

UpToDate has a racism problem: Dr. Stanley Goldfarb

Activists slam private health insurers over coverage restrictions

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Hepatitis C has a cure — but many Americans still lack access to it

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Virginia high school admissions case could be legal follow

Stanford president’s abrupt resignation sparks debate

Anesthesiologist group: stop taking Ozempic before surgery

Are infertility treatments 'essential' during the Covid

knowledge

In rare move, senator releases unverified FBI source report alleging Biden bribe

Extensive review finds private equity owners jack up cost of care

Use doctors trained outside the U.S. to ease the physician shortage

Vertex cell therapy lets patients with type 1 diabetes stop insulin

The stock market has soared this year, but will it last? Experts weigh in

The stock market has soared this year, but will it last? Experts weigh in

explore

focus

leisure time

entertainment